​

GRAIL Stock (NASDAQ:GRAL)

RevenueOwnershipFinancialsChartTranscripts
GRAIL by TradingView

Previous Close

$85.00

52W Range

$12.78 - $103.00

50D Avg

$52.49

200D Avg

$39.35

Market Cap

$3.11B

Avg Vol (3M)

$961.83K

Beta

4.13

Div Yield

-

GRAL Company Profile

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,000

IPO Date

Jun 12, 2024

Website

GRAL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
Americas$108.54M
Non-US$14.69M

Fiscal year ends in Dec 23 | Currency in USD

GRAL Financial Summary

Dec 23Dec 22Dec 21
Revenue$93.11M$55.55M$14.61M
Operating Income$-796.92M$-742.46M$-1.27B
Net Income$-1.47B$-5.40B$-1.25B
EBITDA$-638.22M$-587.70M$-1.21B
Basic EPS$-47.20$-173.87$-40.18
Diluted EPS$-47.20$-173.87$-40.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 12, 25 | 4:30 PM
Q1 25May 13, 25 | 4:30 PM
Q4 24Feb 20, 25 | 4:30 PM

Peer Comparison

TickerCompany
IDYAIDEAYA Biosciences, Inc.
OGNOrganon & Co.
RXRXRecursion Pharmaceuticals, Inc.
DNLIDenali Therapeutics Inc.
BEAMBeam Therapeutics Inc.
IBRXImmunityBio, Inc.
NTLAIntellia Therapeutics, Inc.
HAEHaemonetics Corporation
XRAYDENTSPLY SIRONA Inc.
CONConcentra Group Holdings Parent, Inc.